Definitive Contract HHSN261201300039C
Award Date 9/12/13
Potential Completion Date 8/13/14
Potential Value $299K
Federal Agency
Awardee
Ultimate Awardee
Not listed Federal Contract Vehicle
- Not listed
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Albuquerque, NM 87113, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
12
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed Similar Awards
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Mediomics LLC, a woman-owned small business. The contract is for the development of glycosylation-specific research under SBIR Topic 294, with a ceiling value of $148,569. SBIR contracts are set-aside for small businesses to engage in research and development for the government. This Phase I contract represents the initial research and feasibility...
- <p>This is a $999,898 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Glycobia Inc., a small business, under the SBIR Phase II program. The contract is for the development of chemically defined glycan libraries for use as reference standards and in glycomics research, under a joint NCI-NIGMS program. The contract has a small business set aside designation and runs through September 2018.</p>
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Glycohub, Inc., a woman-owned small business. The contract is for the delivery of chemically defined glycosphingolipid head groups, with a total ceiling value of $298,447.00 and a completion date of December 30, 2014. As an SBIR Phase I contract, this represents the initial research and development effort to explore the feasibility of the proposed technology....
- <p>This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Biotex, Inc. The contract is for the development of glycosylation-specific research, with a ceiling value of $149,919.00 and a completion date of October 14, 2012. The contract is a definitive contract with a firm fixed-price pricing type. This SBIR Phase I action is a set-aside for small businesses.</p>
- This is a firm-fixed-price SBIR Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Chemily LLC, a small business. The contract is for the "CHEMO-ENZYMATIC SYNTHESIS OF STRUCTURALLY DEFINED HYBRID AND COMPLEX-TYPE N-GLYCAN LIBRARIES" and has a ceiling value of $299,544.00. The contract was awarded on September 12, 2013, with an ultimate completion date of October 30, 2014. As an SBIR Phase I contract, this award supports early-stage research and...
- <p>This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a civilian agency, to Omicron Biochemicals, Inc. The $999,991.00 fixed-price contract is for the "Synthesis of High-Mannose N-Glycans" and was awarded on September 18, 2015, with a completion date of September 17, 2017. The contract is a definitive contract, indicating it is a stand-alone award rather than under a larger contract vehicle.</p>
- This is a Small Business Innovation Research (SBIR) contract awarded by the National Institutes of Health's (NIH) National Cancer Institute (NCI) to Glycoscientific, L.L.C., a small business research company. The contract is for the development of glycosylation-specific research reagents, including antibodies and aptamers, under SBIR Topic 294 Phase I. The contract has a ceiling value of $149,951 and was awarded on a firm fixed-price basis. This contract was set aside for total small business...
- <p>This is a $299,999.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Innogenomics Technologies, L.L.C., a minority-owned small business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for research and development in the area of biomedical (basic research). It was awarded on September 22, 2015 with a final completion date of March 21, 2017. The contract has a total small business set-aside designation.</p>
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI) to Siloam Biosciences, Inc., a minority-owned, for-profit manufacturer of goods. The contract, with a ceiling value of $198,570.00, is for the development of a "LOW VOLUME, ULTRA-SENSITIVE IMMUNODIAGNOSTIC SYSTEM" under Topic 309. The contract is a Firm Fixed Price Definitive Contract with a completion date of June 27, 2013. The contract is set aside for small...
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Detroit R&D, Inc., a minority-owned, economically disadvantaged, woman-owned small business. The contract is for R&D in biomedical basic research with a ceiling value of $299,097. The contract is a definitive, firm-fixed-price contract with a period of performance ending on September 21, 2016. This SBIR Phase I award will support the development of...